ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0861

Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
Abstract Number: 0867

Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients
Abstract Number: 0431

Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Abstract Number: 0023

Hypophosphatasia May Be Misdiagnosed as Fibromyalgia: A Single Center Experience
Abstract Number: 0851

Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Abstract Number: 0806

Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Abstract Number: 2043

Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Abstract Number: 0039

Identification of a Regulatory Pathway Governing Expression of TRAF1 via a JIA-associated Non-coding Variant
Abstract Number: 2006

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Abstract Number: 0069

Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Abstract Number: 1311

Identification of Clinical Phenotypes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis According to Peripheral Musculoskeletal Manifestations: A Cluster Analysis in the International ASAS-PerSpA Study
Abstract Number: 0666

Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals
Abstract Number: 0179

Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
Abstract Number: 1338

Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Abstract Number: 1848

Identification of Native and Citrullinated Autoantibodies to Psoriasis Related-antigen PsoP27 in Synovial Fluids of Patients with Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].